Central serous chorioretinopathy treatment granted orphan drug status

  • March 20, 2012

VANCOUVER, British Columbia — The U.S. Food and Drug Administration has granted orphan drug designation to QLT for Visudyne as a potential treatment for chronic or recurrent central serous chorioretinopathy, the company reported in a press release.

QLT is working with external advisers on options for a possible clinical study to assess the safety and efficacy of Visudyne (verteporfin for injection) for central serous chorioretinopathy, according to the release.

Verteporfin is approved worldwide for treatment of predominantly classic subfoveal choroidal neovascularization.

Visudyne saw sales of $22.4 million in QLT's fourth quarter of 2011, representing an 8.4% decrease compared to the same quarter in 2010.

Comments

Healio is intended for health care provider use and all comments will be posted at the discretion of the editors. We reserve the right not to post any comments with unsolicited information about medical devices or other products. At no time will Healio be used for medical advice to patients.

[X]